Botulinum toxin in the management of chronic migraine: clinical evidence and experience
CM Escher, L Paracka, D Dressler… - Therapeutic advances …, 2017 - journals.sagepub.com
Chronic migraine (CM) is a severely disabling neurological condition characterized by
episodes of pulsating unilateral or bilateral headache. The United States Food and Drug …
episodes of pulsating unilateral or bilateral headache. The United States Food and Drug …
The evolution of medication overuse headache: history, pathophysiology and clinical update
C Sun-Edelstein, AM Rapoport, W Rattanawong… - CNS drugs, 2021 - Springer
Medication overuse headache (MOH), the development or worsening of chronic headache
resulting from frequent and excessive intake of medications used for acute treatment of …
resulting from frequent and excessive intake of medications used for acute treatment of …
[HTML][HTML] Integrated care for chronic migraine patients: epidemiology, burden, diagnosis and treatment options
Migraine is a common neurological disorder, characterised by severe headaches.
Epidemiological studies in the USA and Europe have identified a subgroup of migraine …
Epidemiological studies in the USA and Europe have identified a subgroup of migraine …
[HTML][HTML] Chronic migraine plus medication overuse headache: two entities or not?
A Negro, P Martelletti - The journal of headache and pain, 2011 - Springer
Chronic migraine (CM) represents migraine natural evolution from its episodic form. It is
realized through a chronicization phase that may require months or years and varies from …
realized through a chronicization phase that may require months or years and varies from …
Intravenous dihydroergotamine for inpatient management of refractory primary headaches
AJ Nagy, S Gandhi, R Bhola, PJ Goadsby - Neurology, 2011 - AAN Enterprises
Objective: To determine dosing and side effects of dihydroergotamine as they affect
outcomes in primary headache disorders. Methods: We audited our use of …
outcomes in primary headache disorders. Methods: We audited our use of …
Plasma and saliva levels of nerve growth factor and neuropeptides in chronic migraine patients
MU Jang, JW Park, HS Kho, SC Chung… - Oral diseases, 2011 - Wiley Online Library
Oral Diseases (2011) 17, 187–193 Objectives: To investigate the level and interrelationship
of nerve growth factor (NGF) and sensory neuropeptides [substance P (SP), calcitonin gene …
of nerve growth factor (NGF) and sensory neuropeptides [substance P (SP), calcitonin gene …
Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine …
M De Felice, MH Ossipov, R Wang, G Dussor, J Lai… - Brain, 2010 - academic.oup.com
Migraine is a common neurological disorder often treated with triptans. Triptan overuse can
lead to increased frequency of headache in some patients, a phenomenon termed …
lead to increased frequency of headache in some patients, a phenomenon termed …
Pearls and pitfalls in human pharmacological models of migraine: 30 years' experience
In vitro studies have contributed to the characterization of receptors in cranial blood vessels
and the identification of new possible anti-migraine agents. In vivo animal models enable …
and the identification of new possible anti-migraine agents. In vivo animal models enable …
[PDF][PDF] Migraine update
JD Bartleson, FM Cutrer - Minnesota medicine, 2010 - researchgate.net
Migraine Update Page 1 clinical & health affairs | AbstrAct Migraine is a common
intermittently de- bilitating neurovascular disorder that af- fects younger adults, especially …
intermittently de- bilitating neurovascular disorder that af- fects younger adults, especially …
Guidelines for controlled trials of drugs in tension-type headache
The Clinical Trials Subcommittee of the International Headache Society published its first
edition of the guidelines on controlled trials of drugs in tension-type headache in 1995 …
edition of the guidelines on controlled trials of drugs in tension-type headache in 1995 …